How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
The home-flipping sector just hit a milestone. Here's what it means. © 2026 American City Business Journals. All rights reserved. Use of and/or registration on any ...
Page Interworks, P.A., a North Wilkesboro-based mechanical, electrical, plumbing, and fire protection engineering… Wetherill Engineering, Inc. (WEI) was established in 1993 with a focus on structural ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Thomas J Catalano is a CFP and Registered Investment Adviser with the state of South Carolina, where he launched his own financial advisory firm in 2018. Thomas' experience gives him expertise in a ...
Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.
Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results